Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC), the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CNE- and CPE-certified programs, presented by leading, local authorities in tumor immunology and cancer immunotherapy.

These six-hour in-person programs will facilitate understanding of the clinical applications of immunotherapy for disease states with FDA-approved treatments; strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting; and the identification and management of immune-related adverse events.

Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the in-person event, through two Immuno-Oncology (I-O) Cup o' Joe webinars after the program, and indefinitely through a dedicated online CONNECT community forum, which will serve as ongoing resources.

New this year, SITC is partnering with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC) to provide guidance for emergency physicians in identifying and managing patients who present to the ER with immune-related adverse events, and practical information about the necessary hospital operations for providing immunotherapy and strategies for obtaining reimbursement.

Program Overview

Intended Audience

The target audience for ACI program series is patient care providers and others who wish to learn the basic principles of tumor immunology and immunotherapy, and to improve their ability to integrate immunotherapy into state-of-the-art clinical management for their patients. This intended audience includes clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians, allied health professionals, other patient care providers, students and patient advocates.

Program Content

The topics that will be covered during each program in the series are as follows:

• Basic Principles of Cancer Immunotherapy
• Immunotherapy for the Treatment of Melanoma
• Immunotherapy for the Treatment of Lung Cancer
• Immunotherapy for the Treatment of Genitourinary Cancers
• Immunotherapy for the Treatment of Hematologic Malignancies
• Immunotherapy for the Treatment of Head and Neck Cancers
• Effective Practices for Incorporating Immunotherapy into Hospital Operations
• Coverage and Reimbursement Challenges and Strategies
• Mechanisms of Immune-Related Adverse Events
• Nursing Perspective on irAEs: Patient Education, Monitoring and Management
• Management and Mitigation of irAEs for Immunotherapy Prescribers
• Identification and Management of Immune-Related Adverse Events in the Emergency Setting

Educational Objectives

• Describe the rationale for common approaches to cancer immunotherapy.
• Identify the appropriate clinical management of common side effects of immunotherapy agents.
• Implement cancer immunotherapy treatments for melanoma, lung, genitourinary, head and neck, and/or hematologic cancers into clinical practice appropriately.
• Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.
• Provide appropriate care and counsel for patients receiving immunotherapy and their families.
• Provide accurate and appropriate counsel on immunotherapy as part of the treatment team.

ACI program attendees receive access to enduring materials as soon as they are available. Enduring materials are also made available to the public according to a specific timeline.

Click here to learn more about accessing the enduring materials.

2017 Programs

The 2017 ACI series is brought to you in collaboration with the American Academy of Emergency Medicine and Association of Community Cancer Centers.

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact SITC prior to the event at (414) 271-2456.